As the world’s top researchers working in Alzheimer’s disease descend into Toronto for the AAIC this week, all will be coming with a continued show of hope--…

California upstart Tricida has raised its highest level of cash to date with a $55 million Series C funding round backed by major biotech VC players.

The FDA has designated Morphochem’s MCB3837 as a Qualified Infectious Disease Product and simultaneously put the antibiotic on its regulatory fast-track…

Biogen's CEO steps down, Theranos brings on a team to right its wrongs and FDA's Hall leaves for PatientsLikeMe. Plus more hirings, firings and…

This week an FDA panel backed Valeant's skin drug brodalumab and then the regulator gave the thumbs up for an oral version of its constipation drug…

Initially it looked like a U.S. biotech to be the first; then a team funded by the billionaire co-founder of Napster; now, it looks like it will be Chinese…

Cassiopea has taken control of a Phase II trial after the Israeli biotech it licensed the drug from shut down midstudy, delaying the data readout.

InflaRx has raised $34 million in a Series C to at least get it through Phase II testing for its lead candidate, as well as to expand its preclinical pipeline.